#stankostrong…” On April 29, 2024, Jonathan Stanko received a diagnosis of stage four Adenocarcinoma gastric cancer. On May 10, 2024, he shared his journey in a blog post. Jonathan Stanko ...

Concordance between PD-L1 assays 28-8 and SP263 and their respective scoring algorithms in procured upper gastrointestinal adenocarcinoma samples. This is an ASCO Meeting Abstract from the 2025 ASCO ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

The G/GEJ adenocarcinoma market is forecast to be worth $4.72bn in 2029. "BeiGene’s Tevimbra approved in US for first-line gastric cancer treatment" was originally created and published by ...

A Phase III clinical trial of cadonilimab combined with a VEGFR-2 monoclonal antibody for PD-1/L1 inhibitor-pretreated advanced gastric adenocarcinoma and gastroesophageal junction adenocarcinoma ...

Recognising the pressing need for new therapies, the FDA has already granted a fast-track designation to zolbetuximab for the treatment of gastric and GEJ adenocarcinoma. Other companies ...

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

Role of intraperitoneal paclitaxel in eosinophil activation and recruitment in the peritoneal cavity and anti-tumor effects against peritoneal metastasis from gastric cancer. This is an ASCO Meeting ...

in combination with chemotherapy as a first-line option for certain forms of gastric or gastroesophageal carcinoma. Specifically, the anti-PD-1 monoclonal antibody will therefore be available in ...